CU23202A1 - ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES - Google Patents

ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES

Info

Publication number
CU23202A1
CU23202A1 CU20030031A CU20030031A CU23202A1 CU 23202 A1 CU23202 A1 CU 23202A1 CU 20030031 A CU20030031 A CU 20030031A CU 20030031 A CU20030031 A CU 20030031A CU 23202 A1 CU23202 A1 CU 23202A1
Authority
CU
Cuba
Prior art keywords
hepatitis virus
recombinant antigens
vegetable cells
hav
fragments
Prior art date
Application number
CU20030031A
Other languages
English (en)
Inventor
Lay Licel Rodriguez
Martinez Marlen Perez
Ayon Yamilka Rosabal
Bacallao Javier Rios
Velasquez Abel Hernandez
Badillo Beatriz Gonzalez
Quesada Alina Lopez
Gonzalez Rolando Garcia
Sosa Guillermo Selman-Houssein
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20030031A priority Critical patent/CU23202A1/es
Priority to AU2003291913A priority patent/AU2003291913A1/en
Priority to PCT/CU2003/000017 priority patent/WO2004067747A1/es
Priority to MXPA05008221A priority patent/MXPA05008221A/es
Priority to RU2005127340/13A priority patent/RU2005127340A/ru
Priority to EP03767378A priority patent/EP1589111A1/en
Priority to US10/540,615 priority patent/US20060147469A1/en
Priority to CA002510482A priority patent/CA2510482A1/en
Priority to KR1020057012371A priority patent/KR20050100365A/ko
Priority to BR0318026-3A priority patent/BR0318026A/pt
Priority to JP2004567234A priority patent/JP2006514078A/ja
Priority to CNA2003801093588A priority patent/CN1745174A/zh
Priority to ARP040100261A priority patent/AR042960A1/es
Priority to ZA200505187A priority patent/ZA200505187B/en
Publication of CU23202A1 publication Critical patent/CU23202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Generacion de construcciones genÉticas basadas en fragmentos modificados del genoma del virus de la hepatitis A (VHA), utilizando la cepa M2, aislada en Cuba. Laa secuencias nucleotídicas de estos fragmentos fusionados a senales de localizacion y de regulacion apropiadas se expresan en plantas transgÉnicas, dando lugar a antígenos recombinantes del VHA, compuestos por pentAmeros y/o envolturas vacías, capaces de generar una respuesta inmune.
CU20030031A 2003-01-31 2003-01-31 ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES CU23202A1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU20030031A CU23202A1 (es) 2003-01-31 2003-01-31 ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES
AU2003291913A AU2003291913A1 (en) 2003-01-31 2003-12-19 Recombinant hepatitis a virus antigens obtained in plant cells
PCT/CU2003/000017 WO2004067747A1 (es) 2003-01-31 2003-12-19 Antigenos recombinantes del virus de la hepatitis a obtenidos en celulas vegetales
MXPA05008221A MXPA05008221A (es) 2003-01-31 2003-12-19 Antigenos recombinantes del virus de la hepatitis a obtenidos en celulas vegetales.
RU2005127340/13A RU2005127340A (ru) 2003-01-31 2003-12-19 Рекомбинантные антигены вируса гепатита а, полученные в клетках растения
EP03767378A EP1589111A1 (en) 2003-01-31 2003-12-19 Recombinant hepatitis a virus antigens obtained in plant cells
US10/540,615 US20060147469A1 (en) 2003-01-31 2003-12-19 Recombinant hepatitis a virus antigens obtained in plant cells
CA002510482A CA2510482A1 (en) 2003-01-31 2003-12-19 Recombinant hepatitis a virus antigens obtained in plant cells
KR1020057012371A KR20050100365A (ko) 2003-01-31 2003-12-19 식물세포로부터 얻은 재조합 간염 에이 바이러스 항원
BR0318026-3A BR0318026A (pt) 2003-01-31 2003-12-19 Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos
JP2004567234A JP2006514078A (ja) 2003-01-31 2003-12-19 植物細胞内で得られる組換えａ型肝炎ウイルス抗原
CNA2003801093588A CN1745174A (zh) 2003-01-31 2003-12-19 植物细胞中获得的重组甲型肝炎病毒抗原
ARP040100261A AR042960A1 (es) 2003-01-31 2004-01-29 Antigenos recombinantes del virus de la hepatitis a obtenidos en celulas vegetales
ZA200505187A ZA200505187B (en) 2003-01-31 2005-06-27 Recombinant hepatitis A virus antigens obtianed in plant cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030031A CU23202A1 (es) 2003-01-31 2003-01-31 ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES

Publications (1)

Publication Number Publication Date
CU23202A1 true CU23202A1 (es) 2007-05-18

Family

ID=40091669

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030031A CU23202A1 (es) 2003-01-31 2003-01-31 ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES

Country Status (14)

Country Link
US (1) US20060147469A1 (es)
EP (1) EP1589111A1 (es)
JP (1) JP2006514078A (es)
KR (1) KR20050100365A (es)
CN (1) CN1745174A (es)
AR (1) AR042960A1 (es)
AU (1) AU2003291913A1 (es)
BR (1) BR0318026A (es)
CA (1) CA2510482A1 (es)
CU (1) CU23202A1 (es)
MX (1) MXPA05008221A (es)
RU (1) RU2005127340A (es)
WO (1) WO2004067747A1 (es)
ZA (1) ZA200505187B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
KR101012830B1 (ko) * 2008-04-25 2011-02-10 메디칸(주) 신규 ａ형 간염 바이러스의 항원 유전자 및 상기 유전자로형질전환된 식물체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516630A (en) * 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
EP0162054B1 (en) * 1983-09-30 1991-03-06 Massachusetts Institute Of Technology Production of cdna representing hepatitis a viral sequences
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
SU1469856A1 (ru) * 1986-07-31 1990-09-30 Институт биоорганической химии им.М.М.Шемякина Способ конструировани рекомбинантной плазмидной ДНК, кодирующей синтез полипептидных субстанций против гепатита А
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6551820B1 (en) * 1998-12-23 2003-04-22 Boyce Thompson Institute For Plant Research Expression of immunogenic hepatitis B surface antigens in transgenic plants
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine

Also Published As

Publication number Publication date
WO2004067747A1 (es) 2004-08-12
RU2005127340A (ru) 2006-03-10
JP2006514078A (ja) 2006-04-27
MXPA05008221A (es) 2005-10-05
CN1745174A (zh) 2006-03-08
US20060147469A1 (en) 2006-07-06
BR0318026A (pt) 2005-12-06
KR20050100365A (ko) 2005-10-18
EP1589111A1 (en) 2005-10-26
CA2510482A1 (en) 2004-08-12
AU2003291913A1 (en) 2004-08-23
AR042960A1 (es) 2005-07-13
ZA200505187B (en) 2006-04-26

Similar Documents

Publication Publication Date Title
ES2321212T3 (es) Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
JP2009523422A5 (es)
AR044724A1 (es) Promotores del virus de la rizadura amarilla del cestrum
EP2284268A3 (en) Conserved HBV and HCV sequences useful for gene silencing
WO2007097820A3 (en) Viral gene products and methods for vaccination to prevent viral associated diseases
NZ602504A (en) Antiviral vaccines with improved cellular immunogenicity
PT2338508T (pt) Vírus da dengue quimérico recombinante rden3/4delta30(me), rden2/4delta30(me) ou rden1/4delta30(me) contendo uma deleção de 30 nucleótidos (delta30) numa secção da região não traduzida a 3¿ do genoma da dengue de tipo 4, em que a referida deleção de 30 nucleótidos corresponde à estrutura em gancho de cabelo tl2
CY1110704T1 (el) Συστηματα εκφρασης και εμβολια του ανασυνδυαζομενου rna του ιου της ασθενειας newcastle
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
Schaly et al. Baculoviruses in gene therapy and personalized medicine
AR051923A1 (es) Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus
CN102311500B (zh) 一种抗病毒融合蛋白及其应用
PE20161094A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
Di Pilato et al. Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
Stubbs et al. Vesicular stomatitis virus chimeras expressing the Oropouche virus glycoproteins elicit protective immune responses in mice
CU23202A1 (es) ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES
Farman et al. Ebola, the negative stranded RNA virus
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
ZA202005672B (en) Hepatitis b vaccines and uses of the same
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
AR025342A1 (es) Vacuna a subunidades recombinantes